The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Novel targets in AML and their implications for clinical practice
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives a presentation on novel targets in acute myeloid leukemia (AML) and practical strategies for identifying them in the clinic. Dr Loghavi outlines the clinical-grade assays used to detect targetable genetic subtypes, including NPM1-mutated, NUP98-rearranged and KMT2A-rearranged AML. She also highlights that UBTF tandem duplications are often missed by most clinical-grade assays and discusses the importance of determining allelic state in TP53-mutated AML. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
